Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaella Origa

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|March 8, 2016
Deferasirox and children: From clinical trials to the real worldRaffaella Origa, Antonietta Zappu, Maria Loreta Foschini, et al.
Blood Cells, Molecules & Diseases|July 31, 2013
Complexity of the alpha-globin genotypes identified with thalassemia screening in SardiniaRaffaella Origa, Maria E Paglietti, Maria C Sollaino, et al.
American Journal of Hematology|April 21, 2018
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemiasRaffaella Origa, Antonio Piga, Immacolata Tartaglione, et al.
Haematologica|October 13, 2005
Combined therapy with deferiprone and desferrioxamine in thalassemia majorRaffaella Origa, Patrizio Bina, Annalisa Agus, et al.
Experimental Hematology & Oncology|August 15, 2020
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE studyImmacolata Tartaglione, Raffaella Origa, Antonis Kattamis, et al.
American Journal of Hematology|December 30, 2016
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrationsNienke Schotten, Coby M M Laarakkers, Rian W Roelofs, et al.
Blood Transfusion = Trasfusione Del Sangue|July 18, 2025
Transfusion strategies in thalassemia and sickle cell disease SITE-SIMTI-SIdEM Good PracticeGian Luca Forni, Aurora Vassanelli, Lucia De Franceschi, et al.
American Journal of Hematology|January 2, 2024
'Phenoconversion' in adult patients with β-thalassemiaKhaled M Musallam, Susanna Barella, Raffaella Origa, et al.
Annals of Hematology|March 20, 2024
Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort studyKhaled M Musallam, Susanna Barella, Raffaella Origa, et al.
Blood Cells, Molecules & Diseases|May 31, 2024
Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 yearsKhaled M Musallam, Susanna Barella, Raffaella Origa, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|March 8, 2016
Deferasirox and children: From clinical trials to the real worldRaffaella Origa, Antonietta Zappu, Maria Loreta Foschini, et al.
Blood Cells, Molecules & Diseases|July 31, 2013
Complexity of the alpha-globin genotypes identified with thalassemia screening in SardiniaRaffaella Origa, Maria E Paglietti, Maria C Sollaino, et al.
American Journal of Hematology|April 21, 2018
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemiasRaffaella Origa, Antonio Piga, Immacolata Tartaglione, et al.
Haematologica|October 13, 2005
Combined therapy with deferiprone and desferrioxamine in thalassemia majorRaffaella Origa, Patrizio Bina, Annalisa Agus, et al.
Experimental Hematology & Oncology|August 15, 2020
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE studyImmacolata Tartaglione, Raffaella Origa, Antonis Kattamis, et al.
American Journal of Hematology|December 30, 2016
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrationsNienke Schotten, Coby M M Laarakkers, Rian W Roelofs, et al.
Blood Transfusion = Trasfusione Del Sangue|July 18, 2025
Transfusion strategies in thalassemia and sickle cell disease SITE-SIMTI-SIdEM Good PracticeGian Luca Forni, Aurora Vassanelli, Lucia De Franceschi, et al.
American Journal of Hematology|January 2, 2024
'Phenoconversion' in adult patients with β-thalassemiaKhaled M Musallam, Susanna Barella, Raffaella Origa, et al.
Annals of Hematology|March 20, 2024
Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort studyKhaled M Musallam, Susanna Barella, Raffaella Origa, et al.
Blood Cells, Molecules & Diseases|May 31, 2024
Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 yearsKhaled M Musallam, Susanna Barella, Raffaella Origa, et al.
Pageof 10